AARD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Aardvark Therapeutics Inc (AARD) is not a strong buy at this moment for a beginner investor with a long-term strategy. While the company shows potential in its pipeline and has received positive analyst ratings, the lack of significant trading trends, neutral technical indicators, and no recent news or catalysts suggest holding off for now. The financial performance, though improving, remains negative, and no proprietary trading signals are present to justify immediate action.
The MACD is positive and expanding (0.0236), indicating slight bullish momentum. RSI is neutral at 47.751, and moving averages are converging, showing no clear trend. The stock is trading near its pivot point (12.478), with resistance at 12.86 and support at 12.096.
Analysts have initiated coverage with positive ratings and high price targets ($32-$35), citing the company's differentiated approach in obesity and Prader-Willi syndrome treatments. The Phase 3 trial for ARD-101 in Prader-Willi syndrome represents a significant market opportunity.
No recent news or significant trading trends from hedge funds, insiders, or Congress. Financial performance is still negative, with no revenue and a net loss of -$16.3M in the latest quarter. Technical indicators are neutral, and no proprietary trading signals are present.
In 2025/Q3, revenue remained at $0, with no YoY growth. Net income improved by 290.15% YoY but remains negative at -$16.3M. EPS increased by 275% YoY to -0.75, but gross margin is still at 0%.
Analysts from B. Riley, Oppenheimer, and William Blair have initiated coverage with Buy/Outperform ratings and price targets ranging from $32 to $35. They highlight the company's innovative approach in obesity and Prader-Willi syndrome treatments, with ARD-101 showing robust clinical activity and a significant market opportunity.
